Merck stock rises after profit and sales beat, raised outlook

Shares of Merck & Co. Inc. rose 1.4% in premarket trading Thursday, after the drug giant reported third-quarter profit and sale that beat expectations and raised its full-year outlook, as sales of the company’s top 3 selling drugs topped forecasts. Net income fell to $3.25 billion, or $1.28 a share, from $4.57 billion, or $1.80 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share rose to $1.85 from $1.78, beating the FactSet consensus of $1.72. Sales grew 13.7% to $14.96 billion, above the FactSet consensus of $14.07 billion. Keytruda sales jumped 20% to $5.43 billion, topping expectations of $5.41 billion; of Gardasil sales increased 15% to $2.29 billion, above expectations of $2.07 billion. Januvia/Janumet sales fell 15% to $1.13 billion but beat expectations of $1.07 billion. Animal Health sales fell 3% to $1.4 billion, and gross margin contracted to 73.7% from 73.8%. For 2022, Merck raised its guidance ranges for adjusted EPS to $7.32 to $7.37 from $7.25 to $7.35 and for sales to $58.5 billion to $59.0 billion from $57.5 billion to $58.5 billion. Separately, the company said late Wednesday that Robert Davis will succeed Ken Frazier as chief executive officer, as Frazier plans to retire on Nov. 30, 2022. The stock has gained 7.9% over the past three months while the Dow Jones Industrial Average has slipped 1.1%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Previous post Honeywell stock heads higher after earnings as company boosts profit outlook
Next post : Zillow confirms more layoffs amid housing-market slowdown